Aclidinium bromideImage: Ceftolozane/tazobactamImage: Ceftolozane/tazobact	Novel therapeutic drug (INN)	Phase I & II (target indication)	Phase III (target indication)	Phase I, II & III (related indication	Post-approval efficacy requireme	Label information (SmPC/USPI)
CobicistatImage: constraint of the sector of th	Aclidinium bromide					
DTG + 3TC/ABCImage: Constraint of the sector of	Ceftolozane/tazobactam					
ElvitegravirIIIILomitapideIIIINetupitant/palonosetronIIIISelexipagIIIIISucroferric oxyhydroxideIIIISusoctocog alfaIIIIICangrelorIIIIIDaclatasvirIIIIIPeginterferon beta-1aIIIISacubitril/valsartanIIIIVedolizumabIIIIVorapaxarIIIIIvabradineIIIIPeramivirIIIIPimavanserinIIIIImage: Image: Image	Cobicistat					
LomitapideImage: Constraint of the section of the sectio	DTG + 3TC/ABC					
Netupitant/palonosetronImage: Construct on the sector of the	Elvitegravir					
SelexipagImage: selexipagImage: selexipagSucroferric oxyhydroxideImage: selexipagImage: selexipagSusoctocog alfaImage: selexipagImage: selexipagSusoctocog alfaImage: selexipagImage: selexipagSusoctocog alfaImage: selexipagImage: selexipagCangrelorImage: selexipagImage: selexipagCangrelorImage: selexipagImage: selexipagDaclatasvirImage: selexipagImage: selexipagDaclatasvirImage: selexipagImage: selexipagEdoxabanImage: selexipagImage: selexipagPeginterferon beta-1aImage: selexipagImage: selexipagSacubitril/valsartanImage: selexipagImage: selexipagVedolizumabImage: selexipagImage: selexipagVorapaxarImage: selexipagImage: selexipagConj. estrogens/bazedoxifeneImage: selexipagImage: selexipagIvabradineImage: selexipagImage: selexipagImage: selexipagPeramivirImage: selexipagImage: selexipagImage: selexipagPeramivirImage: selexipagImage: selexipagImage: selexipagPimavanserinImage: selexipagImage: selexipagImage: selexipag	Lomitapide					
Sucroferric oxyhydroxideImage: Susoctocog alfaImage: Susoct	Netupitant/palonosetron					
Susoctocog alfaIIIIICangrelorIIIIIIDaclatasvirIIIIIIEdoxabanIIIIIIPeginterferon beta-1aIIIIISacubitril/valsartanIIIIIVedolizumabIIIIIIVorapaxarIIIIIIIvabradineIIIIIIPetiromerIIIIIIPeramivirIIIIIIPimavanserinIIIIII	Selexipag					
CangrelorImage: Comparison of the compari	Sucroferric oxyhydroxide					
DaclatasvirImage: Comparison of the compa	Susoctocog alfa					
EdoxabanImage: Comparison of the sector of the	Cangrelor		•••			0
Peginterferon beta-1aImage: Constant in the sector of the sec	Daclatasvir	0	0	0	0	
Sacubitril/valsartanImage: Sacubitril/valsartanImage: Sacubitril/valsartanImage: Sacubitril/valsartanVedolizumabImage: Sacubitril/valsartanImage: Sacubitril/valsartanImage: Sacubitril/valsartanImage: Sacubitril/valsartanVorapaxarImage: Sacubitril/valsartanImage: Sacubitril/valsartanImage: Sacubitril/valsartanImage: Sacubitril/valsartanV	Edoxaban			0		
VedolizumabImage: second s	Peginterferon beta-1a					
VorapaxarImage: strogens/bazedoxifeneImage: strogens/bazedoxifeneParaminizedoxifeneoParaminizedoxifeneo	Sacubitril/valsartan					
Conj. estrogens/bazedoxifeneOIIvabradineIOIPatiromerOIOPeramivirOOIPimavanserinIOI	Vedolizumab					
Ivabradine Ivabradine Patiromer Ivabradine Ivabradine <td>Vorapaxar</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Vorapaxar					
PatiromerOImage: Constraint of the second sec	Conj. estrogens/bazedoxifene		0			
PeramivirOOOOPimavanserinOOO	Ivabradine			0		
Pimavanserin O O	Patiromer	0				0
	Peramivir	0	0			0
Teriflunomide OOO	Pimavanserin				0	
	Teriflunomide	0	0			0

Figure S1 – Overview of supportive 'confirmatory' evidence of efficacy

Overview of supportive non-pivotal clinical trials, regulatory requests for post-approval confirmation of efficacy and description of supportive data in the EU Summary of Product Characteristics (SmPC) or US Product Information (USPI). Color shading signifies drugs fulfilling our criteria for supportive data in EU only (BLUE closed circles), in US only (RED open circles) or in both regions (BLUE/RED double circles). Examples of sources of supportive data included bioequivalence data to allow bridging from supportive Phase III data obtained with a different route of administration (e.g. DTG + 3TC/ABC and peramivir); pharmacodynamic studies in healthy subjects showing effect on a clinically relevant marker (e.g. netupitant/palonosetron); efficacy data obtained from randomized, controlled trials conducted in identical or related patient population(s) from both pre-specified (e.g. edoxaban and vedolizumab) and post-hoc subgroup analyses (e.g. cangrelor and ivabradine); efficacy data obtained from open-label extension studies (e.g. daclatasvir and elvitegravir); and efficacy data from flawed (e.g. conjugated estrogens/bazedoxifene) or failed studies (e.g. cangrelor, pimavanserin and vorapaxar). There were no examples of data from databases or registries ('real world' data) providing supportive evidence. The supportive trials were not consistently described in the product label.

ents

ns)